SCHEMBL7140334

SCHEMBL7140334

CC(=O)Nc1ccc(-c2c[nH]c(-c3ccccc3O)n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.51
MEN1 O00255 9/20 0.51
MAPT P10636 7/20 0.51
ALDH1A1 P00352 7/20 0.51
KDM4E B2RXH2 7/20 0.51
HPGD P15428 4/20 0.51
RXFP1 Q9HBX9 3/20 0.51
NPSR1 Q6W5P4 1/20 0.51
CYP2C19 P33261 1/20 0.51
ERCC1 P07992 1/20 0.50
ERCC4 Q92889 1/20 0.50
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
CASP3 P42574 2/20 0.48
SENP7 Q9BQF6 2/20 0.48
ATM Q13315 1/20 0.48
POLB P06746 2/20 0.46
PRNP P04156 1/20 0.46
GAA P10253 1/20 0.46
SENP8 Q96LD8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17280212 0.82 KMT2A (0.57) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL28897775 0.79 SMN1; SMN2 (0.62) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL26467077 0.77 KMT2A (0.49) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL13962486 0.77 KMT2A (0.61) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL13203481 0.76 ALDH1A1 (0.62) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL8986487 0.75 DCUN1D1 (0.49) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL28483060 0.75 KMT2A (0.56) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL13938614 0.75 KMT2A (0.66) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL7138395 0.74 NQO2 (0.58) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL7392835 0.73 ERCC1 (0.55) KMT2AMEN1MAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP disclosed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO disclosed